Standard and experimental therapy in cutaneous T-cell lymphomas

Area of Science:

• Dermatology
• Oncology
• Immunology

Background:

• Cutaneous T-cell lymphomas (CTCLs) are diverse lymphoproliferative disorders.
• Characterized by clonal lymphocytes accumulating in the skin.
• Skin-directed therapies are the primary first-line treatment approach.

Purpose of the Study:

• To review current and emerging therapeutic strategies for CTCL.
• To highlight advancements in both topical and systemic treatments.
• To discuss the evidence base and limitations in treatment recommendations.

Main Methods:

• Review of current literature on CTCL treatments.
• Identification of novel topical agents like retinoids and gene therapy (adenovirus-interferon-gamma).
• Summary of systemic therapies including biologicals (fusion molecules, monoclonal antibodies, immune response modifiers) and antiproliferative drugs (methotrexate).

Main Results:

• Emerging topical therapies show promise, including retinoids and gene therapy.
• Systemic treatments encompass a range of biologicals and well-tolerated antiproliferative agents.
• Established evidence-based treatment recommendations exist for CTCL.

Conclusions:

• The treatment landscape for CTCL is evolving with new topical and systemic options.
• Despite existing recommendations, the lack of large randomized trials hinders definitive evidence.
• Further research is needed to establish robust, evidence-based treatment guidelines.